Recombinant Collagen 7 Dosing for Skin Integrity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Dystrophic Epidermolysis Bullosa (DEB), particularly the recessive form (RDEB), lacks effective treatments, leading to severe skin fragility, chronic blistering, and debilitating scarring due to mutations in the COL7A1 gene that impair the production of functional collagen VII, resulting in poor epidermal-dermal adherence and lack of normal anchoring fibrils.
Innovation Solution
Administering recombinant human collagen 7 (rhCol7) protein systemically via intravenous infusion to deposit at the dermal-epidermal junction, promoting the formation of anchoring fibrils and improving skin integrity, with a dosing regimen that includes an initial higher dose followed by a maintenance phase to sustain therapeutic benefits.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If systemic protein therapy with recombinant human Col7 is administered to treat DEB, then skin integrity and wound healing are improved, but the complexity of the treatment protocol increases
Solution Approach 1:
The patent employs parameter changes by systematically varying dosing frequency (from weekly to monthly intervals) and dose amounts to optimize therapeutic effect while managing treatment complexity. The protocol transitions from an intensive loading phase to a maintenance phase, adjusting parameters based on clinical response and Col7 deposition levels.
Solution Approach 2:
The treatment protocol includes a preliminary loading phase with more frequent dosing to rapidly establish therapeutic levels of Col7 in the skin, followed by a maintenance phase. This preliminary action ensures adequate protein deposition before reducing treatment frequency, thereby improving reliability while managing long-term complexity.
2Productivity
If frequent dosing is used to establish therapeutic levels of Col7, then skin integrity improves faster, but treatment time and patient burden increase
Solution Approach 1:
The patent implements periodic action through a structured dosing schedule that alternates between intensive loading phases (more frequent dosing) and maintenance phases (less frequent dosing). This periodic approach accelerates initial therapeutic effect while managing long-term treatment duration and patient burden.
Solution Approach 2:
The loading phase performs preliminary action by rapidly establishing therapeutic Col7 levels through frequent dosing, after which the maintenance phase sustains these levels with less frequent administration. This resolves the contradiction by concentrating treatment intensity when most needed, then reducing frequency.
3Reliability
If high doses of rhCol7 are administered to rapidly improve wound healing, then therapeutic effect is enhanced, but production cost and treatment expense increase
Solution Approach 1:
The patent applies dynamics by making the dose amount variable rather than fixed. The protocol uses higher doses during the loading phase to rapidly achieve therapeutic effect, then transitions to lower maintenance doses. This dynamic dosing strategy enhances wound healing efficacy while reducing the total quantity of rhCol7 required over time.
Solution Approach 2:
The treatment protocol changes the dose parameter over time, starting with higher amounts to establish therapeutic levels quickly, then reducing to maintenance amounts. This parameter change resolves the contradiction by concentrating substance use when most beneficial, then minimizing ongoing requirements.
4Stability of the object's composition
If long-term systemic administration is used to maintain therapeutic benefits, then skin fragility and scarring are reduced, but risk of adverse effects and immune response increases
Solution Approach 1:
The patent uses periodic action with scheduled dosing intervals that allow the body to adapt to the therapeutic protein over time. By spacing doses appropriately and transitioning from loading to maintenance phases, the protocol maintains skin stability while minimizing cumulative adverse effects and immune responses associated with continuous high-level exposure.
Data Source
AI summary
The present disclosure relates to collagen 7 (Col7) protein replacement therapy for treatment of a skin disorder, specifically dystrophic epidermolysis bullosa (DEB). Recombinant collagen 7 drug products. compositions, and methods for administration and monitoring the outcomes of the treatment are provided.